INOVIO PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-84.9M | $-107.3M | $-135.1M | $-279.8M | $-303.7M | $-166.4M | $-119.4M | $-97.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.4M | $1.8M | $2.6M | $3.7M | $3.0M | $3.0M | $3.6M | $3.7M |
| Amortization | — | $0 | $145.4K | $496.5K | $520.4K | $547.1K | $1.1M | $1.2M |
| Stock-Based Compensation | $3.8M | $6.6M | $11.1M | $22.6M | $26.3M | $15.6M | $10.9M | $10.7M |
| Net Cash from Operating Activities | $-88.6M | $-104.1M | $-124.4M | $-216.2M | $-215.7M | $-178.0M | $-97.9M | $-73.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $285.7K | $487.8K | $320.9K | $969.2K | $1.2M | $1.5M | $987.9K | $2.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $14.0M | $104.1M | $87.4M | $109.6M | $-175.3M | $-58.8M | $-9.0M | $42.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $53.1M | $51.5M | $5.0M | $81.8M | $211.5M | $465.3M | $105.4M | $31.0M |
| Net Change in Cash | $-21.5M | $51.5M | $-32.0M | $-24.8M | $-179.6M | $228.5M | $-1.5M | $-92.9K |
| Free Cash Flow | $-88.9M | $-104.6M | $-124.7M | $-217.2M | $-216.9M | $-179.5M | $-98.8M | $-75.6M |